PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.CME information and select publications here.

Episode metadata supplied by the publisher feed · Published May 15, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

0:00 51:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Prostate Cancer Update?

This episode is 51 minutes long.

When was this Prostate Cancer Update episode published?

This episode was published on May 15, 2026.

Can I download this Prostate Cancer Update episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!